1. Introduction {#sec1}
===============

Anthracycline antibiotics belong to the group of anticancer drugs. They were originally isolated from cultures of *Streptomyces*. Anthracyclines are widely used in the treatment of neoplastic diseases such as leukemia, breast cancer, and AIDS-related Kaposi\'s sarcoma. They also demonstrate activity against tumors of the ovaries, lung, testes, prostate, cervix, bladder, and Ewing\'s sarcoma \[[@B1]--[@B3]\]. The most widely used anthracyclines are doxorubicin (DOX), daunorubicin (DAU), and epidoxorubicin (EPI) \[[@B4]--[@B6]\] ([Figure 1](#fig1){ref-type="fig"}). Their low bioavailability necessitates parenteral administration \[[@B7], [@B8]\], which requires sterility \[[@B14]\] obtained mainly by filtration. Given the considerable exposure of medical personnel to anthracycline antibiotics and their adsorption to most surfaces, especially those of sterilization filters, there is a need to find new sterilization methods that do not rely on filtration. Although radiation sterilization is an effective alternative, the structure of drugs may alter as a consequence of exposure to irradiation. The aglycone attached to the aminosugar with a glycoside bond may be prone to cleavage resulting from electron transfer within the molecule. Stability studies demonstrated degradation of anthracycline antibiotics in solutions, under the influence of increased temperature and when exposed to light in the solid state as well as a consequence of combining chemotherapy with radiotherapy \[[@B15]--[@B20]\]. Regarding the effects of radiation sterilization on anthracycline antibiotics, only DOX was studied in that respect with a focus on the impact of a standard dose of 25 kGy on its stability \[[@B21]\]. As DAU and EPI are widely used in anticancer pharmacotherapy, those antibiotics also require analysis of their vulnerability to ionizing radiation.

The aim of this work was to assess the possibility of applying radiation sterilization to DOX, DAU, and EPI as active substances or conversion-induced impurities.

2. Materials and Methods {#sec2}
========================

2.1. Samples {#sec2.1}
------------

DOX, DAU, and EPI were synthesized at the Institute of Biotechnology and Antibiotics, Department of Modified Antibiotics, Warsaw, Poland. They were reddish powders, freely soluble in water and methanol. Sodium lauryl sulfate, phosphoric acid, and all other chemicals were obtained from Merck KGaA (Germany) and were of analytical or high-performance liquid chromatographic grade.

2.2. Irradiation {#sec2.2}
----------------

0.025 g samples of each substance were placed in 3 mL colorless glass vials that were closed with plastic stoppers. The samples in the vials were exposed to beta irradiation in a linear electron accelerator LAE 13/9 (9.96 MeV electron beam and 6.2 *μ*A current intensity) until they absorbed doses of 25, 50, 100, 200, and 400 kGy.

2.3. Electron Paramagnetic Resonance (EPR) Spectroscopy {#sec2.3}
-------------------------------------------------------

Detection of free radicals and determination of their concentration were carried out using a Bruker ELEXSYS 500 spectrometer (X-band) at 297 K. EPR spectra were recorded as a first derivative of the absorption signal. The number of free radicals was calculated using the integration procedure described elsewhere \[[@B22]\].

2.4. UV-Vis Spectroscopy {#sec2.4}
------------------------

Chemical changes in nonirradiated and irradiated samples were analyzed by using a UV-Vis Varian Carry 100 spectrophotometer. 2 mg of each sample was dissolved in 20.0 mL of methanol. 1.0 mL of the so-obtained solution was diluted to 10.0 mL with methanol. The final concentration of the solutions was 0.01 mg/mL. Absorption spectra of the so-prepared solutions were recorded in the wavelength range 190--900 nm.

2.5. IR Spectroscopy {#sec2.5}
--------------------

IR spectra of nonirradiated and irradiated anthracyclines were taken with the use of a Thermo Scientific Nicolet iS10 spectrophotometer with the Omnic software. The infrared transmittance spectra of the crystalline samples were recorded after a time necessary to achieve plateaus in EPR study, in the frequency range from 400 to 7500 cm^−1^, at room temperature.

2.6. HPLC Analysis {#sec2.6}
------------------

An HPLC Waters Alliance e2695 system was used for chromatographic separation of the degradation products of nonirradiated and irradiated DOX, DAU and EPI samples. All the samples (1 mg/mL) were dissolved in the mobile phase. A Symmetry C18 (250 × 4.6 mm, 5 *μ*m) analytical column was employed as a stationary phase. The mobile phase consisted of solution A (acetonitrile) and solution B (2.88 g of sodium lauryl sulfate and 2.25 g of phosphoric acid(*V*) 85% in 1000 mL) (50 : 50, v : v). UV detection was performed at 254 nm. The flow rate was 1.0 mL/min. The injected volume was 5 *μ*L.

2.7. Theoretical Analysis {#sec2.7}
-------------------------

All the calculations were made by using the Gaussian 03 package \[[@B23]\]. In order to interpret the experimental results of IR absorption scattering, quantum chemical calculations were performed based on a density functional theory (DFT) method with the B3LYP hybrid functional and 6-31G(d,p) basis set.

3. Results and Discussions {#sec3}
==========================

The first EPR analysis was performed 1 day after irradiation for samples exposed to a dose of 25 kGy. DOX, DAU, and EPI irradiated at 25 kGy contained about 3.94 × 10^15^ spins/g, 1.37 × 10^15^ spins/g, and 2.44 × 10^15^ spins/g, respectively. Exponential decay of unstable free radical was observed with the half-time of 4 days in DAU and DOX and 7 days in EPI after irradiation. The EPR signals of the sterilized anthracycline antibiotics were very weak. The plateaus of free radical concentrations versus time for DOX and DAU appeared after about 10 days, whereas for EPI after 20 days. EPR spectra after these periods consisted approximately of only stable free radicals.

The analytical study was conducted during a period when only stable free radicals were detected by EPR. The impact of an irradiation dose size on the structure of DAU, DOX, and EPI was studied at 0, 25, 50, 100, 200, and 400 kGy without the presence of unstable free radical in EPR spectra. By using UV-Vis spectroscopy the location and the intensity of the absorption maximum were determined, whereas IR spectroscopy was employed to establish the intensity, location, and type of characteristic vibrations. For the DAU, DOX, and EPI samples no significant changes in the location (\~289 nm, \~233 nm, and 221 nm) or intensity of the absorption maximum were recorded (Figures [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}). The spectra of their nonirradiated and irradiated samples did not show any essential differences in the value of absorbance. All samples exhibited two absorption maxima, at 233 nm and 251 nm. The IR spectra of DOX, DAU, and EPI were compared with the theoretical spectra based on the density functional theory. The main characteristic vibrations obtained from the IR spectra are collected in [Table 1](#tab1){ref-type="table"}. The conformation between the calculated and experimental spectra is quite good. The most significant is the region between 700 and 1800 cm^−1^, where intense and characteristic bands related to intramolecular vibrations of the molecules are observed, including the deformation of rings as well as stretching of various C--C bonds (Figures [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and [7](#fig7){ref-type="fig"}). Vibrational spectra of the nonirradiated and irradiated samples of the three samples are very similar. We did not observe any change in the position and shape of the bands. This suggests that the radiation sterilization does not influence the stability of the DOX, DAU, and EPI. Similar results were received by comparing SEM images of the nonirradiated and irradiated samples. Taking into account the biological activity of the most important impurities specified by Ph. Eur. \[[@B14]\], changes in the concentration of the main substances in the presence of those impurities were analyzed (Figures [8](#fig8){ref-type="fig"}, [9](#fig9){ref-type="fig"}, [10](#fig10){ref-type="fig"}, [11](#fig11){ref-type="fig"}, [12](#fig12){ref-type="fig"}, and [13](#fig13){ref-type="fig"}). By separating the compounds to be examined from the impurities, it was possible to assess changes in their content before and after irradiation at 25 kGy. It was found that exposure to such a dose of radiation did not produce any changes in the concentrations of the main substances or the impurities.

Slight alterations were registered when the samples of DAU, DOX, and EPI were exposed to greater doses of radiation. Under such conditions, EPI demonstrated the greatest content change, and the presence of unstable free radicals was noted for the longest period of time. It was also proved, by observing the mass balance, that the main substances did not convert into unknown impurities. Similar studies of some tetracycline analogs showed that the aglycon was stable when irradiated at 25 kGy and that changes occurred when greater radiation doses were applied \[[@B24]\]. It may therefore be proposed that not only a modification of the aglycon structure but also its ability to bind with a sugar moiety of specific stereoisomerism are the factors that stabilize the structures of analogs of anthracycline antibiotics.

4. Conclusions {#sec4}
==============

The current study of the impact of radiation sterilization on the stability of DAU, DOX, and EPI demonstrates that this kind of sterilization may be an alternative to filtration recommended for sterilizing analogs of anthracycline antibiotics. The effect of radiation sterilization on the stability of DAU, DOX, and EPI depends on the structure of a particular compound. With regard to those analogs, it is important to assay the postirradiation content of the main substance in the presence of all possible related substances in order to determine whether other degradation products or postirradiation conversion occur.
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###### 

Main characteristic vibrational modes of daunorubicin (DAU), doxorubicin (DOX), and epidoxorubicin (EPI) observed in experimental and calculated spectra.

  Calculation (cm^−1^)   Experimental (cm^−1^)   Band assignment                              
  ---------------------- ----------------------- ----------------- ------------ ------ ------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  723                    736                     736               764          761    761    C--C--C *b* in a ring + def. aglycone group + breathing tetrahydropyran ring in aminosugar group + NH~2~  *w*
                                                                                              
  752                    754                     749               795          795    795    NH~2~   *w* + C--C--C *b* in aminosugar group + C--H *w* at **d** ring and in aminosugar group
                                                                                              
  776                    773                     774               816          804    805    C--C--C *b* in a ring + def. aglycone group + breathing tetrahydropyran ring in aminosugar group + CH~2~  *r* at **d** ring
                                                                                              
  931                    930                     935               940          939    939    C--O--H *b* at c ring + C--H *w* in aminosugar group
                                                                                              
  959                    957                     951               955          949    949    C--C--C *b* in **d** ring + NH~2~   *w* + CH *w* at **d** ring and aminosugar group
                                                                                              
  984                    ---                     ---                                          CH~3~  *w* in COCH~3~ group
                                                                                              
  1010                   1008                    1006              986          990    989    Breathing aglycone group + CH~2~   *r* + NH~2~   *r* + CH~3~   *w* in COCH~3~ + CH~2~   *w* in COCH~2~OH
                                                                                              
  1021                   1029                    1032              1008         1005   1005   Breathing **a** ring + def. aglycone group + C--O *s* at **a** ring + C--O--H *b* at **c** ring + NH~2~   *w* + CH~3~   *w* in COCH~3~ group
                                                                                              
  1079                   1078                    1065              1070         1072   1072   C--O *s* between tetrahydropyran ring and O--H group in aminosugar group
                                                                                              
  1105                   1104                    1104              1085         1089   1089   C--O *s* in metoxy group at **a** ring + C--C--C *b* in **a** ring + CH~2~   *r*
                                                                                              
  1123                   1123                    1122              1109         1114   1114   C--O *s* in tetrahydropyran ring + C--O *s* in glycosidic bond + C--C *s* in **d** ring + C--H *w* in CH~3~ in aminosugar group
                                                                                              
  1137                   1139                    1136              1109         1114   1114   C--C *s* in **d** ring and in tetrahydropyran ring in aminosugar group + C--H *b* at **d** ring and in tetrahydropyran ring in aminosugar group + CH~3~   *w* in COCH~3~ group + C--O *s* in COCH~2~OH group
                                                                                              
  1157                   1157                    1156              1153         1143   1143   C--O *s* in glycosidic bond + C--O *s* between tetrahydropyran ring and O--H group in aminosugar group + C--H *r* in CH~3~ in aminosugar group + def. **d**ring
                                                                                              
  1206                   1205                    1200              1194         1201   1201   C--O *s* in glycosidic bond + C--C *s* I d ring + C--H *b* at **d** ring and aminosugar group
                                                                                              
  1226                   1225                    1221              1205         1211   1211   CH~2~   *t* at **d** ring + breathing **a** ring + C--O--H *b* at **c** ring
                                                                                              
  ---                    1239                    1239                           1235   1235   C--O--H *b* in COCH~2~OH group
                                                                                              
  1278                   1275                    1275              1262         1263   1263   C--O--H *b* at c ring + C--C *s* in aglycone group + CH~2~   *t* in COCH~2~OH group
                                                                                              
  1291                   1290                    1293              1289         1284   1285   C--O--H *b* at **c** ring + breathing **a** and **c** ring
                                                                                              
  1317                   1317                    1318              1289         1284   1285   Breathing **c** ring + C--O *s* at **c** ring + C--O *s* at **a** ring + CH~2~  *w* at **a** ring +C--H *w* at **d** ring
                                                                                              
  1329                   1329                    1330              1317         1318   1318   C--O *s* at a ring + breathing **a** and **c** ring
                                                                                              
  1367                   1367                    1366              1374         1374   1374   C--C--C *b* in **d** ring + C--C *s* in **a** and **b** ring + C--O *s* at **c** ring + C--O-- *b* at **c** ring
                                                                                              
  1404                   ---                     ---                                          CH~3~  sc in COCH~3~ group
                                                                                              
  1425                   1427                    1423              1404         1413   1413   O--C--H *b* + N--C--H *b*
                                                                                              
  1476                   1476                    1478              1474         1471   1472   C--O *s* at c ring + def. **c** ring + CH~3~   *umbrella mode* at **a** ring + C--O--H *b* at **c** ring
                                                                                              
  1502                   1502                    1505              1506         1507   1507   C--O--H *b* at **c** ring + CH~3~  sc at **a** ring + C--C *s* in aglycone group
                                                                                              
  1524                   1524                    1527                           1525   1524   C--O--H *b* at c ring + CH~3~  sc at **a** ring + C--C *s* in aglycone group
                                                                                              
  1614                   1615                    1615              1576         1582   1581   C--C *s* in **c** ring + C--O--H *b* at **c** ring + C=O *s* at **b** ring + C--C *s* in **a** ring
                                                                                              
  1640                   1640                    1642              1576         1582   1581   C--C *s* in **a** ring + C--O--H *b* at **c** ring + CH~3~   *w* at **a** ring
                                                                                              
  1661                   1663                    1663              1617         1616   1616   NH~2~  sc
                                                                                              
  1688                   1688                    1688              1617         1616   1616   C=O *s* at **b** ring + C--O--H *b* at **c** ring
                                                                                              
  1744                   1744                    1745              1707         1717   1717   C=O *s* at **b** ring
                                                                                              
  1791                   1808                    1807              1716         1730   1730   C=O *s* at **d** ring
                                                                                              
  2967--3237                                                       2844--3108                 C--H *s*
                                                                                              
  3009                   3010                    2960              2878         2896   2896   O--H *s* at **c** ring
                                                                                              
  3488                   3488                    3485                                         N--H *s* symmetric
                                                                                              
  3566                   3566                    3571                                         N--H *s* antisymmetric
                                                                                              
  3630                   3634                    3639              3161         3326   3329   O--H *s*
                                                                                              
  3791                   3788                    3785                           3527   3527   O--H *s*
                                                                                              
  3809                   3801                    ---                                          O--H *s*
                                                                                              
  ---                    3831                    3831                           3545   3545   O--H *s* in COCH~2~OH group

Vibrational modes---*s*: stretching, *b*: bending, *w*: wagging, *sc*: scissoring, *r*: rocking, and *t*: twisting.
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